Biomea Fusion, Inc. (BMEA)
0.6001
+0.02
(+2.58%)
USD |
NASDAQ |
Oct 23, 16:00
0.6117
+0.01
(+1.93%)
After-Hours: 20:00
Biomea Fusion Enterprise Value : 9.182M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 9.182M |
| October 22, 2026 | 8.087M |
| October 21, 2026 | 15.71M |
| October 20, 2026 | 19.00M |
| October 19, 2026 | 26.24M |
| October 16, 2026 | 28.67M |
| October 15, 2026 | 26.31M |
| October 14, 2026 | 26.14M |
| October 13, 2026 | 57.01M |
| October 12, 2026 | 64.26M |
| October 09, 2026 | 68.61M |
| October 08, 2026 | 64.99M |
| October 07, 2026 | 61.36M |
| October 06, 2026 | 56.29M |
| October 05, 2026 | 59.91M |
| October 02, 2026 | 57.74M |
| October 01, 2026 | 59.91M |
| September 30, 2026 | 62.09M |
| September 29, 2026 | 57.01M |
| September 28, 2026 | 59.19M |
| September 25, 2026 | 61.36M |
| September 24, 2026 | 73.68M |
| September 23, 2026 | 70.06M |
| September 22, 2026 | 88.91M |
| September 21, 2026 | 89.63M |
| Date | Value |
|---|---|
| September 18, 2026 | 98.33M |
| September 17, 2026 | 95.43M |
| September 16, 2026 | 91.81M |
| September 15, 2026 | 96.16M |
| September 14, 2026 | 94.71M |
| September 11, 2026 | 91.81M |
| September 10, 2026 | 88.91M |
| September 09, 2026 | 99.42M |
| September 08, 2026 | 105.58M |
| September 04, 2026 | 112.83M |
| September 03, 2026 | 104.13M |
| September 02, 2026 | 105.94M |
| September 01, 2026 | 96.16M |
| August 31, 2026 | 87.46M |
| August 28, 2026 | 91.08M |
| August 27, 2026 | 87.46M |
| August 26, 2026 | 89.63M |
| August 25, 2026 | 91.08M |
| August 24, 2026 | 80.93M |
| August 21, 2026 | 64.99M |
| August 20, 2026 | 64.26M |
| August 19, 2026 | 66.44M |
| August 18, 2026 | 63.54M |
| August 17, 2026 | 63.54M |
| August 14, 2026 | 61.36M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| REGENXBIO, Inc. | 506.54M |
| Compass Therapeutics, Inc. | -33.20M |
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.328M |
| Total Expenses (Quarterly) | 8.328M |
| EPS Diluted (Quarterly) | -0.1151 |
| Earnings Yield | -82.84% |
| Normalized Earnings Yield | -116.28 |